Child and adolescent psychopharmacology in the new millennium

A workshop for academia, industry, and government

Joseph Deveaugh-Geiss, John March, Mark Shapiro, Paul J. Andreason, Graham Emslie, Lisa M. Ford, Laurence Greenhill, Dianne Murphy, Ernest Prentice, Rosemary Roberts, Susan Silva, James M. Swanson, Barbara Van Zwieten-Boot, Benedetto Vitiello, Karen Wagner, Barry Mangum

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Objective: To give academic researchers, government officials, and industry scientists an opportunity to assess the state of pediatric psychopharmacology and identify challenges facing professionals in the field. Method: Increased federal spending and the introduction of pediatric exclusivity led to large increases in pediatric psychopharmacology research in the 1990s. Despite the increase in research, concerns exist about methods and incentives for making new medications available for use in pediatric psychiatric disorders. In recognition of these concerns, the Duke Clinical Research Institute held a roundtable in September 2004. Participants from the National Institutes of Health, regulatory agencies, academia, and the pharmaceutical industry spoke about the effects of government regulations such as the U.S. Food and Drug Administration Modernization Act and the Pediatric Research Equity Act on pediatric research from academic, clinical, and industry perspectives, and bioethical considerations of such research. Conclusions: To ensure development of new drugs for treating psychiatric disorders in children and adolescents, we must address the challenges posed by the regulatory environment governing pediatric psychopharmacology research. Strategies were identified for improving the evidence base for psychopharmacologic interventions in youth before widespread use and for more effectively defining a research agenda for the future.

Original languageEnglish (US)
Pages (from-to)261-270
Number of pages10
JournalJournal of the American Academy of Child and Adolescent Psychiatry
Volume45
Issue number3
DOIs
StatePublished - Mar 2006

Fingerprint

Psychopharmacology
Industry
Pediatrics
Education
Research
Psychiatry
Government Regulation
National Institutes of Health (U.S.)
Drug Industry
United States Food and Drug Administration
Social Change
Motivation
Research Personnel
Pharmaceutical Preparations

Keywords

  • Best Pharmaceuticals for Children Act
  • Pediatric depression
  • Pediatric psychopharmacology
  • Pediatric Research Equity Act
  • Psychopharmacology trials

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Developmental and Educational Psychology

Cite this

Child and adolescent psychopharmacology in the new millennium : A workshop for academia, industry, and government. / Deveaugh-Geiss, Joseph; March, John; Shapiro, Mark; Andreason, Paul J.; Emslie, Graham; Ford, Lisa M.; Greenhill, Laurence; Murphy, Dianne; Prentice, Ernest; Roberts, Rosemary; Silva, Susan; Swanson, James M.; Van Zwieten-Boot, Barbara; Vitiello, Benedetto; Wagner, Karen; Mangum, Barry.

In: Journal of the American Academy of Child and Adolescent Psychiatry, Vol. 45, No. 3, 03.2006, p. 261-270.

Research output: Contribution to journalArticle

Deveaugh-Geiss, J, March, J, Shapiro, M, Andreason, PJ, Emslie, G, Ford, LM, Greenhill, L, Murphy, D, Prentice, E, Roberts, R, Silva, S, Swanson, JM, Van Zwieten-Boot, B, Vitiello, B, Wagner, K & Mangum, B 2006, 'Child and adolescent psychopharmacology in the new millennium: A workshop for academia, industry, and government', Journal of the American Academy of Child and Adolescent Psychiatry, vol. 45, no. 3, pp. 261-270. https://doi.org/10.1097/01.chi.0000194568.70912.ee
Deveaugh-Geiss, Joseph ; March, John ; Shapiro, Mark ; Andreason, Paul J. ; Emslie, Graham ; Ford, Lisa M. ; Greenhill, Laurence ; Murphy, Dianne ; Prentice, Ernest ; Roberts, Rosemary ; Silva, Susan ; Swanson, James M. ; Van Zwieten-Boot, Barbara ; Vitiello, Benedetto ; Wagner, Karen ; Mangum, Barry. / Child and adolescent psychopharmacology in the new millennium : A workshop for academia, industry, and government. In: Journal of the American Academy of Child and Adolescent Psychiatry. 2006 ; Vol. 45, No. 3. pp. 261-270.
@article{6c327fe161a346edb750d5c9f33f802b,
title = "Child and adolescent psychopharmacology in the new millennium: A workshop for academia, industry, and government",
abstract = "Objective: To give academic researchers, government officials, and industry scientists an opportunity to assess the state of pediatric psychopharmacology and identify challenges facing professionals in the field. Method: Increased federal spending and the introduction of pediatric exclusivity led to large increases in pediatric psychopharmacology research in the 1990s. Despite the increase in research, concerns exist about methods and incentives for making new medications available for use in pediatric psychiatric disorders. In recognition of these concerns, the Duke Clinical Research Institute held a roundtable in September 2004. Participants from the National Institutes of Health, regulatory agencies, academia, and the pharmaceutical industry spoke about the effects of government regulations such as the U.S. Food and Drug Administration Modernization Act and the Pediatric Research Equity Act on pediatric research from academic, clinical, and industry perspectives, and bioethical considerations of such research. Conclusions: To ensure development of new drugs for treating psychiatric disorders in children and adolescents, we must address the challenges posed by the regulatory environment governing pediatric psychopharmacology research. Strategies were identified for improving the evidence base for psychopharmacologic interventions in youth before widespread use and for more effectively defining a research agenda for the future.",
keywords = "Best Pharmaceuticals for Children Act, Pediatric depression, Pediatric psychopharmacology, Pediatric Research Equity Act, Psychopharmacology trials",
author = "Joseph Deveaugh-Geiss and John March and Mark Shapiro and Andreason, {Paul J.} and Graham Emslie and Ford, {Lisa M.} and Laurence Greenhill and Dianne Murphy and Ernest Prentice and Rosemary Roberts and Susan Silva and Swanson, {James M.} and {Van Zwieten-Boot}, Barbara and Benedetto Vitiello and Karen Wagner and Barry Mangum",
year = "2006",
month = "3",
doi = "10.1097/01.chi.0000194568.70912.ee",
language = "English (US)",
volume = "45",
pages = "261--270",
journal = "Journal of the American Academy of Child and Adolescent Psychiatry",
issn = "0890-8567",
publisher = "Elsevier Limited",
number = "3",

}

TY - JOUR

T1 - Child and adolescent psychopharmacology in the new millennium

T2 - A workshop for academia, industry, and government

AU - Deveaugh-Geiss, Joseph

AU - March, John

AU - Shapiro, Mark

AU - Andreason, Paul J.

AU - Emslie, Graham

AU - Ford, Lisa M.

AU - Greenhill, Laurence

AU - Murphy, Dianne

AU - Prentice, Ernest

AU - Roberts, Rosemary

AU - Silva, Susan

AU - Swanson, James M.

AU - Van Zwieten-Boot, Barbara

AU - Vitiello, Benedetto

AU - Wagner, Karen

AU - Mangum, Barry

PY - 2006/3

Y1 - 2006/3

N2 - Objective: To give academic researchers, government officials, and industry scientists an opportunity to assess the state of pediatric psychopharmacology and identify challenges facing professionals in the field. Method: Increased federal spending and the introduction of pediatric exclusivity led to large increases in pediatric psychopharmacology research in the 1990s. Despite the increase in research, concerns exist about methods and incentives for making new medications available for use in pediatric psychiatric disorders. In recognition of these concerns, the Duke Clinical Research Institute held a roundtable in September 2004. Participants from the National Institutes of Health, regulatory agencies, academia, and the pharmaceutical industry spoke about the effects of government regulations such as the U.S. Food and Drug Administration Modernization Act and the Pediatric Research Equity Act on pediatric research from academic, clinical, and industry perspectives, and bioethical considerations of such research. Conclusions: To ensure development of new drugs for treating psychiatric disorders in children and adolescents, we must address the challenges posed by the regulatory environment governing pediatric psychopharmacology research. Strategies were identified for improving the evidence base for psychopharmacologic interventions in youth before widespread use and for more effectively defining a research agenda for the future.

AB - Objective: To give academic researchers, government officials, and industry scientists an opportunity to assess the state of pediatric psychopharmacology and identify challenges facing professionals in the field. Method: Increased federal spending and the introduction of pediatric exclusivity led to large increases in pediatric psychopharmacology research in the 1990s. Despite the increase in research, concerns exist about methods and incentives for making new medications available for use in pediatric psychiatric disorders. In recognition of these concerns, the Duke Clinical Research Institute held a roundtable in September 2004. Participants from the National Institutes of Health, regulatory agencies, academia, and the pharmaceutical industry spoke about the effects of government regulations such as the U.S. Food and Drug Administration Modernization Act and the Pediatric Research Equity Act on pediatric research from academic, clinical, and industry perspectives, and bioethical considerations of such research. Conclusions: To ensure development of new drugs for treating psychiatric disorders in children and adolescents, we must address the challenges posed by the regulatory environment governing pediatric psychopharmacology research. Strategies were identified for improving the evidence base for psychopharmacologic interventions in youth before widespread use and for more effectively defining a research agenda for the future.

KW - Best Pharmaceuticals for Children Act

KW - Pediatric depression

KW - Pediatric psychopharmacology

KW - Pediatric Research Equity Act

KW - Psychopharmacology trials

UR - http://www.scopus.com/inward/record.url?scp=33645100012&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645100012&partnerID=8YFLogxK

U2 - 10.1097/01.chi.0000194568.70912.ee

DO - 10.1097/01.chi.0000194568.70912.ee

M3 - Article

VL - 45

SP - 261

EP - 270

JO - Journal of the American Academy of Child and Adolescent Psychiatry

JF - Journal of the American Academy of Child and Adolescent Psychiatry

SN - 0890-8567

IS - 3

ER -